Bayer exec says it can line up cash for 'significant' buyout; Biogen, Samsung tie the knot on biosim venture;

@FierceBiotech: Targeting the NOX2/ROS pathway: Cincinnati Children's debuts new anti-inflammatory drug class--via @MarkHFierce. Story | Follow @FierceBiotech

@JohnCFierce: BMS amps up academic partnerships with PhII project at Duke. Item | Follow @JohnCFierce

@RyanMFierce: Fake Avastin ingredients: salt, starch, chemicals and a big dose of pure evil. Article | Follow @RyanMFierce

@FierceMedDev: OPTIMEDICA starts U.S. shipments of CATALYS precision laser system,1st patients treated at Mann Eye Institute, Houston. Release | Follow @FierceMedDev

> Bayer's CFO told analysts today the pharma giant could pull off a "significant" acquisition. Story

> Biogen Idec ($BIIB) and the multinational Samsung have formally set up their new joint venture to develop biosimilars. Christopher Hansung Ko has been named CEO of Samsung Bioepis and the facilities are currently under construction in Korea. Release

> Ultragenyx Pharmaceutical says the FDA has granted the orphan drug designation to UX003 for the treatment of MPS 7. Release

Pharma News

@FiercePharma: Pfizer buys Emergen-C maker Alacer. 500m packets of vitamin powder a year for $PFE's "supplement portfolio"--Bloomberg. Item | Follow @FiercePharma

> Phony Avastin vials contained chemicals, but no drugs. Item

> FDA puts Xarelto's ACS indication on fast track. Article

Manufacturing News

> Cargo theft in Brazil violent and growing. Article

> Lilly outlines $442M Ireland plans. Story

> Birth control redux: Glenmark Generics pulling mixed-up pills. News

> FDA device regulator calls for more authority. More

Research News

> Rats 'shoot blanks' with U Kansas male contraceptive. More

> MGH's Tilly morphs human ovarian stem cells into eggs. News

> Heart muscle-cell gel can treat cardiac damage, maybe carry drugs. Article

> Brain switch turns 'on' when danger hits, 'off' when threat passes. Item

And Finally… After getting started in a trailer, Quintiles today is celebrating its 30th birthday with a host of experimental drugs in clinical trials. Story

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.